Y-mAbs Therapeutics
Linlin Wang began working as a Research Fellow/Associate at Memorial Sloan Kettering Cancer Center in July 2015. In this role, they focused on developing bispecific antibodies for immunotherapy against solid tumors. They also studied T-cell infiltration and the anti-tumor effect. They worked at Memorial Sloan Kettering Cancer Center until September 2019. In September 2019, Linlin Wang joined Y-mAbs Therapeutics, Inc. as a Senior Scientist, and is currently in that role.
Linlin Wang obtained a Doctor of Philosophy (Ph.D.) degree in Chemistry from New York University, where they studied from 2009 to 2015.
Y-mAbs Therapeutics
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.